Analysts Raise Forecasts for Major Firms Following Strong Q1 Earnings Surprises

Financial analysts have upwardly revised their price targets for Johnson & Johnson (JNJ), BlackRock (BLK), and Citigroup (C) following robust quarterly performances. RBC Capital raised its price target for JNJ to $265.00, as the company now targets double-digit growth by 2030, banking on its Innovative Medicine strength and MedTech gains. While JNJ anticipates headwinds from the drug Stelara, it plans to offset this impact through strategic new product launches to sustain operational sales growth. Meanwhile, BlackRock reported results that surpassed Wall Street estimates, and Citigroup analysts increased forecasts following strong quarterly profits. These upward revisions signal growing confidence in the ability of these industry leaders to maintain long-term growth momentum across the healthcare and financial sectors.